Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Neuro-reproductive toxicity and carcinogenicity of 1-bromopropane - studies for evidence-based preventive medicine (EBPM).
J Occup Health
January 2025
Department of Occupational and Environmental Health, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.
Bromopropane was introduced commercially as an alternative to ozone-depleting and global warming solvents. The identification of 1-bromopropane neurotoxicity in animal experiments was followed by reports of human cases of 1-bromopropane toxicity. In humans, the most common clinical features of 1-bromopropane neurotoxicity are decreased sensation, weakness in extremities, and walking difficulties.
View Article and Find Full Text PDFEffect of Ozoralizumab Administration with or without Methotrexate in Patients with Rheumatoid Arthritis: A Post-Hoc Analysis.
Rheumatol Ther
January 2025
Saitama Medical University, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Introduction: Ozoralizumab (OZR) is a novel tumor necrosis factor (TNF) inhibitor that was launched in Japan for treating patients with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies. This post-hoc analysis aimed to compare the efficacy of OZR administered without methotrexate (MTX) with placebo or OZR administration in combination with MTX.
Methods: We analyzed the OZR group (30 mg) in the NATSUZORA trial (non-MTX, open trial) (OZR group; n = 94) and the placebo group (MTX group; n = 75) and the 30-mg OZR group (OZR + MTX group; n = 152) in the OHZORA trial (combined MTX, double-blind trial), and the covariates were adjusted by propensity score matching.
Shepherd with goiter in the late-Renaissance Nativity scene of the Canonica di San Salvatore in Barzanò.
J Endocrinol Invest
January 2025
School of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, I-20900, Monza, Italy.
EAACI Clinical and Research Fellowship Program: Shaping the Future of Allergy and Clinical Immunology.
Allergy
January 2025
Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.
Mediation of modifiable risk factors in two multidomain dementia prevention trials.
Alzheimers Dement
January 2025
Department of Public and Occupational Health, Amsterdam UMC Location VUMC, Amsterdam, the Netherlands.
Introduction: We explored which dementia risk factors in two multidomain prevention trials mediate beneficial, neutral, or counteracting effects on dementia incidence.
Methods: We pooled data from the multidomain MAPT (Multidomain Alzheimer Preventive Trial; n = 1679, up to 5-year follow-up) and preDIVA trials (Prevention of Dementia by Intensive Vascular Care; n = 3526, up to 12-year follow-up) in adults aged 70+. We used multiple mediation analysis to quantify the role of 2-year changes in body mass index, systolic blood pressure, total cholesterol, and physical activity in the intervention effects on dementia incidence.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!